Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase

International Journal of Cancer

Volumn 121, Issue 9, 2007, Pages 2095-2104

  Xiao, Xia ^a   Wu, Jiangxue ^a,d   Zhu, Xiaofeng ^a   Zhao, Peng ^a   Zhou, Jinlin ^a   Quentin, Qiang Liu ^a   Zheng, Limin ^a   Zeng, Musheng ^a   Liu, Ranyi ^a   Huang, Wenlin ^a,b,c,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c Guangzhou Doublle Bio product Inc   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Epidermal growth factor receptor; Nasopharyngeal carcinoma; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor; ZD6474

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE; VANDETANIB; VASCULOTROPIN RECEPTOR;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REDUCTION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34648816362     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22955     Document Type: Article

References (44)

1. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO. Novel 4-anilino-quinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active. VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002;45:1300-12.
2. Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 2005;11:1268-76.
3. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
4. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;729:58-70.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
6. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65.
7. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33.
8. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997;16:750-9.
9. Ryan AJ, Wedge SR. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005;92 (Suppl 1):S6-S13.
10. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target forZD6474. Cancer Res 2004;64:9101-4.
11. Li JH, Li P, Klamut H, Liu FF. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines. Clin Cancer Res 1997;3:507-14.
12. Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995;32:859-77.
13. Weinrib L, Li JH, Donovan J, Huang D, Liu FF. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Cancer Gene Ther 2001;8:352-60.
14. Li JH, Lax SA, Kim J, Klamut H, Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1999;43:607-16.
15. Li JH, Shi W, Chia M. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther 2003;8:964-73.
16. Cheung ST, Huang DP, Hui AB. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999;83:121-6.
17. Wu J, Xiao X, Zhao P, Xue G, Zhu Y, Zhu X, Zheng L, Zeng Y, Huang W. Minicircle-IFNγ induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res 2006;12:4702-13.
18. McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ, Ellis LM. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004;3:1041-8.
19. Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D, Zeng YX. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 2001;169:27-32.
20. Sun Y, Fry DW, Vincent P, Nelson JM, Elliott W, Leopold WR. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res 1999;19:919-24.
21. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007;120:796-805.
22. Das A, Banik NL, Ray SK. Mechanism of apoptosis with the involvement of calpain and caspase cascades in human malignant neuroblastoma SH-SY5Y cells exposed to flavonoids. Int J Cancer 2006;119:2575-85.
23. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 2006;119:2557-66.
24. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003;13:65-70.
25. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571-83.
26. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
27. Detjen KM, Murphy D, Welzel M, Farwig K, Wiedenmann B, Rosewicz S. Downregulation of p21(waf/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma. Exp Cell Res 2003;282:78-89.
28. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-23.
29. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
30. Green DR. Apoptosis. Death deceiver. Nature 1998;396:629-30.
31. Park MT, Choi JA, Kim MJ, Um HD, Bae S, Kang CM, Cho CK, Kang S, Chung HY, Lee YS, Lee SJ. Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J Biol Chem 2003;278:50624-34.
32. Gross A, Jockei J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998;17:3878-85.
33. Rossig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeier S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 2002;277:9684-9.
34. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9.
35. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.
36. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
37. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
38. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002;8:1076-8.
39. Kumar R, Hung MC. Signaling intricacies take center stage in cancer cells. Cancer Res 2005;65:2511-15.
40. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
41. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-48.
42. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 1996;88:1770-6.
43. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47.
44. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.